BLRX | BioLineRx Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2781 - 0.2979
52 Week Range	0.2500 - 1.8900
Beta	1.34
Implied Volatility	911.73%
IV Rank	37.71%
Day's Volume	259,205
Average Volume	761,247
Shares Outstanding	95,193,074
Market Cap	26,749,254
Sector	Healthcare
Industry	Biotechnology
IPO Date	2011-07-27

Valuation
Profitability
Growth
Health
P/E Ratio	-0.94
Forward P/E Ratio	N/A
EPS	-0.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	79
Country	Israel
Website	BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BLRX's peers: ALDX, ARDX, LXRX, MCRB, IBRX, XFOR, MREO, INZY, TERN, LPTX, VRCA, VRNA, GRTX, ARQT, PLX, CDTX, FBIO, MBIO, ACHL, APTO, FBIOP, CANF, CGEN, CTXR, ENLV, EYEN, ORMP, PPBT, PLUR

*Chart delayed

Analyzing fundamentals for BLRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see BLRX Fundamentals page.

Watching at BLRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BLRX Technicals page.